Denteric’s GPV381 enters Phase 2, but can a therapeutic vaccine really change periodontitis care?
Denteric’s GPV381 has entered Phase 2 in periodontitis. Read why the gingipain-targeting vaccine could test a new treatment model.
Pharma & Biotech
Pharma & Biotech
Gilead targets durable autoimmune remission with $2.18bn Ouro Medicines acquisition
Gilead Sciences acquires Ouro Medicines for up to $2.18bn, adding BCMA T cell engager gamgertamig to its inflammation pipeline. Analysis of what the deal reveals.
Pharma & Biotech
Will Surf’s SUSTAIN platform bring at-home neuromodulation to mainstream rheumatology?
Surf begins human trial for ultrasound-based neuromodulation in RA. Can it challenge biologics? Find out what this means for autoimmune therapy access.
Pharma & Biotech
Ventyx to give Lilly an oral inflammation pipeline—what’s the real upside?
Eli Lilly and Company has announced plans to acquire Ventyx Biosciences Inc. in an all-cash transaction valued at approximately $1.2 billion, securing a portfolio of clinical-stage oral small molecule therapeutics focused on chronic inflammatory-mediated diseases. The deal includes NLRP3 inhibitors such as VTX2735 and VTX3232, alongside two Phase 2 programs for inflammatory bowel disease. The
Pharma & Biotech
Sobi bets $950m on Arthrosi to reshape chronic gout treatment with pozdeutinurad
Swedish Orphan Biovitrum AB (Sobi) has entered into a definitive agreement to acquire Arthrosi Therapeutics Inc. for $950 million upfront and up to $550 million in milestone payments. The deal brings the investigational gout drug pozdeutinurad (AR882) into Sobi’s pipeline, positioning the oral URAT1 inhibitor as a potential anchor asset in a late-stage inflammatory franchise.
Pharma & Biotech
Why ALK-Abelló’s investment in Allegria signals a strategic shift in allergic disease treatment
Allegria Therapeutics has secured USD 5.1 million in a seed extension financing round led by ALK-Abelló, with additional participation from HighLight Capital, the Lichtsteiner Foundation, and existing backer Forty51 Ventures. The Swiss biotechnology company will use the funds to nominate its first clinical candidate and advance its portfolio of mast cell-modulating therapies for allergy and